[go: up one dir, main page]

WO2005067898A3 - Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques - Google Patents

Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques Download PDF

Info

Publication number
WO2005067898A3
WO2005067898A3 PCT/US2005/000393 US2005000393W WO2005067898A3 WO 2005067898 A3 WO2005067898 A3 WO 2005067898A3 US 2005000393 W US2005000393 W US 2005000393W WO 2005067898 A3 WO2005067898 A3 WO 2005067898A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
insulin
compositions
release compositions
pulmonary administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/000393
Other languages
English (en)
Other versions
WO2005067898A2 (fr
Inventor
Stelios Tzannis
Nancy Dasovich
Sandeep Kumar
Negar Sadrzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority to EP05705167A priority Critical patent/EP1701714A2/fr
Publication of WO2005067898A2 publication Critical patent/WO2005067898A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005067898A3 publication Critical patent/WO2005067898A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions à libération prolongée faciles à élaborer, garantissant la longévité de la protéine d'utilité pharmaceutique à délivrer. Les compositions en question renferment des complexes insolubles de cette protéine et un agent de précipitation selon une proportion appropriée, donnant ainsi le profil de libération prolongée souhaité. L'agent considéré peut appartenir à un groupe de divers agents : cations métalliques divalents, sels de la série de Hofmeister et ajusteurs de pH. On décrit en particulier des compositions qui renferment de l'insuline, appropriées à une délivrance pulmonaire.
PCT/US2005/000393 2004-01-07 2005-01-07 Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques Ceased WO2005067898A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05705167A EP1701714A2 (fr) 2004-01-07 2005-01-07 Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53518504P 2004-01-07 2004-01-07
US60/535,185 2004-01-07

Publications (2)

Publication Number Publication Date
WO2005067898A2 WO2005067898A2 (fr) 2005-07-28
WO2005067898A3 true WO2005067898A3 (fr) 2009-02-26

Family

ID=34794347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/000393 Ceased WO2005067898A2 (fr) 2004-01-07 2005-01-07 Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques

Country Status (3)

Country Link
US (2) US7192919B2 (fr)
EP (1) EP1701714A2 (fr)
WO (1) WO2005067898A2 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
CA2183577C (fr) 1994-03-07 2007-10-30 John S. Patton Methodes et compositions pour l'administration pulmonaire d'insuline
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
CA2479751C (fr) 2002-03-20 2008-06-03 Trent Poole Appareil d'inhalation
EP1701714A2 (fr) * 2004-01-07 2006-09-20 Nektar Therapeutics Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
SI1740154T1 (sl) * 2004-03-12 2009-10-31 Biodel Inc Insulinski sestavki z izboljšano absorpcijo
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
WO2005115441A2 (fr) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions et methodes ameliorees d'administration par les muqueuses de l'hormone parathyroide
EP2626368B1 (fr) * 2004-07-19 2016-12-21 Biocon Limited Conjugués insuline-oligomère, formulations et utilisations de ceux-ci
CA2575692C (fr) 2004-08-20 2014-10-14 Mannkind Corporation Catalyse de la synthese de dicetopiperazine
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
US20090011976A1 (en) * 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
ES2640282T3 (es) 2005-09-14 2017-11-02 Mannkind Corporation Método de formulación de fármacos basado en el aumento de la afinidad de superficies de micropartículas cristalinas para agentes activos
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
EP1986679B1 (fr) 2006-02-22 2017-10-25 MannKind Corporation Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
WO2008013955A2 (fr) * 2006-07-27 2008-01-31 Nektar Therapeutics Formulations à libération prolongée pour administration pulmonaire
EP2076242B8 (fr) * 2006-07-27 2013-02-20 Nektar Therapeutics Formulations de dérivés d'insuline pour administration pulmonaire
WO2008124522A2 (fr) * 2007-04-04 2008-10-16 Biodel, Inc. Formulations contenant de l'amyline
EP2597103B1 (fr) * 2007-11-16 2016-11-02 Novo Nordisk A/S Composition pharmaceutique durable comprenant du liraglutide et du degludec
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2904623T3 (es) 2008-06-20 2022-04-05 Mannkind Corp Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
PL3228320T3 (pl) 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
KR101639098B1 (ko) * 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
DK2498801T3 (en) 2009-11-13 2018-05-07 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
SI2554183T1 (en) 2009-11-13 2018-08-31 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
CA2809666C (fr) 2010-08-30 2020-09-22 Michael M. Lipp Formulations de poudre seche et methodes de traitement de maladies pulmonaires
KR101823320B1 (ko) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
EP2464346A1 (fr) 2010-08-30 2012-06-20 Pulmatrix, Inc. Méthodes de traitement de la mucoviscidose
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP3470057B1 (fr) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Poudres sèches cationiques contenants un sel de magnésium
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
DK2750699T3 (en) 2011-08-29 2015-10-26 Sanofi Aventis Deutschland A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014DN03093A (fr) 2011-10-24 2015-05-15 Mannkind Corp
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
CA2907566C (fr) 2013-04-01 2023-08-22 Pulmatrix, Inc. Poudres seches de tiotropium
BR112015024659A8 (pt) 2013-04-03 2019-12-17 Sanofi Sa formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015148905A1 (fr) 2014-03-28 2015-10-01 Mannkind Corporation Utilisation d'insuline à action ultrarapide
TN2017000235A1 (en) 2014-12-12 2018-10-19 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10245241B2 (en) * 2016-06-01 2019-04-02 Nina S Yoshpe Nasal irrigation
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
WO1996032149A1 (fr) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Administration par voie pulmonaire de medicaments en aerosols
WO1998016205A2 (fr) * 1996-10-17 1998-04-23 Inhale Therapeutic Systems Compositions stables en poudre a l'etat vitreux
EP1273290A1 (fr) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Particules poreuses de grande taille émises par inhalateur

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
DK0592540T3 (da) 1991-07-02 2000-06-26 Inhale Inc Fremgangsmåde og indretning til aflevering af aerosoliserede medikamenter
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
ES2205560T5 (es) 1997-09-29 2013-04-16 Novartis Ag Preparaciones estabilizadas para usar en inhaladores de dosis medida
ATE238768T1 (de) * 1998-06-24 2003-05-15 Advanced Inhalation Res Inc Grosse poröse partikel ausgestossen von einem inhalator
WO2001000674A1 (fr) 1999-06-29 2001-01-04 Eli Lilly And Company Cristaux d'insuline administres par voie pulmonaire
ES2343124T3 (es) 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
EP1701714A2 (fr) * 2004-01-07 2006-09-20 Nektar Therapeutics Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
WO1996032149A1 (fr) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Administration par voie pulmonaire de medicaments en aerosols
WO1998016205A2 (fr) * 1996-10-17 1998-04-23 Inhale Therapeutic Systems Compositions stables en poudre a l'etat vitreux
EP1273290A1 (fr) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Particules poreuses de grande taille émises par inhalateur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The United States Pharmacopeia USP 24. National Formulary NF 19", 1999, UNITED STATES PHARMACOPEIAL CONVENTION, ROCKVILLE USA, XP002350887 *

Also Published As

Publication number Publication date
EP1701714A2 (fr) 2006-09-20
US20050203002A1 (en) 2005-09-15
US7192919B2 (en) 2007-03-20
WO2005067898A2 (fr) 2005-07-28
US20080031966A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2005067898A3 (fr) Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2004093795A3 (fr) Compositions d'administration de combinaisons de medicaments
WO2006034373A8 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
WO2008036147A3 (fr) Administration de médicament avec biopolymères sensibles aux stimuli
WO2008067389A3 (fr) Modulation de maladies neurodégénératives
WO2008000483A3 (fr) Composés organiques
IL198930A0 (en) Non-standard amino acid conjugates of amphetamine and processes for making and using the same
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2008098168A3 (fr) Ectoparasiticide à action prolongée à haute dose pour contrôle étendu
WO2010009120A3 (fr) Nouveaux sels et polymorphes d'analogues de polyéther de désazadesferrithiocine comme agents de chélation de métaux
MX2007003907A (es) Agentes terapeuticos con toxicidad reducida.
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2007133944A3 (fr) Administration topique d'acyclovir
WO2007075972A3 (fr) Formulations de chlorite et leurs procédés de préparation et d'utilisation
IL198180A (en) Salt p- toluene 5-amino-3-sulfonic acid (2'-0-acetyl-3'-deoxy-ß-d-riboforanosyl) -3h-thiazole [5,4- d] pyrimidine-2-on crystalline form , A pharmaceutical product containing it, its use in the preparation of a drug and methods for its manufacture
PL1916995T5 (pl) Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie
WO2008070141A3 (fr) Compositions pour administrer des agents thérapeutiques
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2007109093A3 (fr) Derives de pyrazolo[1,5-a]pyrimidine et procedes d'utilisation de ceux-ci
MX2007003196A (es) Agente y alimento para evitar/mejorar el trastorno digestivo funcional.
WO2006121522A3 (fr) Capteurs et pompes implantables, agents anticicatrisants, et compositions therapeutiques
BRPI0810192A2 (pt) Aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diazaespir o [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.
WO2007056236A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse
UA83900C2 (en) Amorphous forms of risedronate monosodium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005705167

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005705167

Country of ref document: EP